Evogene Ltd. EVGN
Set alert
0.37 USD -0.01 -1.45%
At close · Oct 30
0.37 0.00 -0.40%
After hours · Oct 30, 4:00 PM ET
0.3653 Day range 0.3799
0.36 52-week range 1.26
- YTD
- -65.95%
- 1 year
- -69.54%
- Open
- 0.3775
- Prev close
- 0.3801
- Mkt cap
- 5.09M
- Vol
- 14.77K
- Avg vol
- 1.42M
- EPS
- -1.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3653
- High
- 0.3799
- Forward P/E
- -0.39
- Beta
- 1.08
- Short ratio
- 0.04
- Inst. own
- 11.12%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.87
- 200-d avg
- 4.76
- 1y target
- 8.13
5Y chart
Events in this range
- Sep 12, 2022Rating: Aegis Capital · — → Buy
- May 2, 2023Rating: Lake Street · — → Buy
- Jul 21, 2023Rating: Roth MKM · Buy → Buy
- Aug 17, 2023Earnings: -1.7; estimate -1.9; surprise 10.53%
- Aug 18, 2023Rating: Lake Street · Buy → Buy
- Oct 2, 2023Rating: Alliance Global Partners · — → Buy
- Nov 15, 2023Earnings: -0.8; estimate -1.7; surprise 52.94%
- Mar 7, 2024Earnings: -1.3; estimate -1.4; surprise 7.14%
- May 23, 2024Earnings: -0.8; estimate 0; surprise —%
- Jul 25, 2024Split: 1 for 10
- Aug 22, 2024Earnings: -1.06; estimate 0; surprise —%
- Aug 23, 2024Rating: Lake Street · Buy → Buy
- Nov 21, 2024Earnings: -1.31; estimate 0; surprise —%
Signals (86)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 29, 2026 | 2 days ago |
| MACD: Sell Signal | Oct 19, 2026 | 1 week ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| RSI: Oversold | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 25, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | Feb 16, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 29, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 9, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 9, 2024 | 1 year ago |
| RSI: Oversold | Oct 7, 2024 | 2 years ago |
| RSI: Oversold | Aug 26, 2024 | 2 years ago |
| SMA: Bearish | Jun 3, 2024 | 2 years ago |
| SMA: Bearish | May 27, 2024 | 2 years ago |
| SMA: Bullish | May 20, 2024 | 2 years ago |
| SMA: Bullish | May 20, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 25, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| SMA: Bullish | Jan 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 22, 2024 | 2 years ago |
| SMA: Bearish | Jan 22, 2024 | 2 years ago |
| SMA: Bullish | Dec 18, 2023 | 2 years ago |
| SMA: Bearish | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Dec 4, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 27, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| SMA: Bearish | Aug 14, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| RSI: Overbought | Jul 10, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | May 29, 2023 | 3 years ago |
| SMA: Bullish | May 22, 2023 | 3 years ago |
| SMA: Bearish | May 15, 2023 | 3 years ago |
| SMA: Bullish | May 8, 2023 | 3 years ago |
| MACD: Buy Signal | May 8, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 20, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Feb 27, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bullish | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| SMA: Bearish | Dec 26, 2022 | 3 years ago |
| SMA: Bullish | Dec 19, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 12, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jul 18, 2022 | 4 years ago |
| SMA: Bearish | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 21, 2022 | 4 years ago |
Key statistics
- Market cap
- 9.17M
- Enterprise value
- 5.18M
- Trailing P/E
- 0.00
- Forward P/E
- -0.39
- PEG ratio
- 0.00
- Price / sales
- 0.97
- Price / book
- 0.57
- EPS (TTM)
- -4.46
- Beta
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -210.25%
- Revenue (TTM)
- 9.45M
- Revenue growth
- 39.80%
- Free cash flow
- -2.42M
- Total cash
- 20.91M
- Total debt
- 810.00K
- Return on equity
- -82.37%
- Shares outstanding
- 6.79M
- Short % of float
- 0.42%
- 50-day average
- 1.87
- 200-day average
- 4.76
Analyst view
Consensus: none
Price target (mean) 8.13 +2069.0% upside
Now 0.3746
- Target (low)
- 5.00
- Target (mean)
- 8.13
- Target (high)
- 11.25
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.725.
Financials — quick view
EVGN Revenue — quarterly 347.00K
EVGN Net income — quarterly -1.77M
EVGN EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 21, 2024 | Sep 1, 2024 | 0.00 | -1.31 | — | — |
| Aug 22, 2024 | Jun 1, 2024 | 0.00 | -1.06 | — | — |
| May 23, 2024 | Mar 1, 2024 | 0.00 | -0.80 | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -1.40 | -1.30 | +0.10 | +7.14% |
| Nov 15, 2023 | Sep 1, 2023 | -1.70 | -0.80 | +0.90 | +52.94% |
| Aug 17, 2023 | Jun 1, 2023 | -1.90 | -1.70 | +0.20 | +10.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2024 | Lake Street | main | Buy | Buy |
| Oct 2, 2023 | Alliance Global Partners | init | — | Buy |
| Aug 18, 2023 | Lake Street | main | Buy | Buy |
| Jul 21, 2023 | Roth MKM | main | Buy | Buy |
| May 2, 2023 | Lake Street | init | — | Buy |
| Sep 12, 2022 | Aegis Capital | main | — | Buy |
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- evogene.com
News
- Evogene Announces Acute Graft-Versus-Host Disease As Target Indication For Its Internal Drug Discovery Program
- Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
- Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Evogene Reaches Agreement With Pure Capital Group To Resolve Differences
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Evogene Discloses That Another Nasdaq 180-Day Period For Regaining Minimum Bid Price Requirement Has Been Extended Until March 29, 2027
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- CORRECTION: Evogene Q2 EPS $(0.13) Beats $(0.27) Estimate, Sales $347.000K Beat $325.000K Estimate
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on EVGN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SilverArc Capital Management, LLC | 0.61% | 308,550 | 416.54K | Mar 30, 2024 |
| Morgan Stanley | 0.06% | 28,404 | 38.34K | Mar 30, 2024 |
| BNP Paribas Financial Markets | 0.02% | 9,140 | 12.34K | Mar 30, 2024 |
| LPL Financial LLC | 0.01% | 6,684 | 9.02K | Mar 30, 2024 |
| JP Morgan Chase & Company | 0.01% | 3,943 | 5.32K | Mar 30, 2024 |
| UBS Group AG | 0.01% | 6,250 | 8.44K | Mar 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 5,901 | 7.97K | May 30, 2024 |